17: Rasha Al-Lamee On ORBITA, ISCHEMIA, Coronary Revascularisation & Stable Ischemic Heart Disease
Recorded before the American Heart Association (AHA) Scientific Sessions 2019, Ankur is joined by Rasha K Al-Lamee, Interventional Cardiologist at Imperial College Healthcare NHS Trust in London and Study Director of the Objective Randomised Blinded Investigation with Optimal Medical Therapy of Angioplasty in Stable Angina (ORBITA) trial. Rasha talks about how she got into academia, the significance of her end-of-training PhD, and what led to the genesis of ORBITA.
Ankur and Rasha also discuss the findings and unanswered questions of ORBITA, and how recent research in coronary revascularisation and stable ischemic heart disease has (or has not) changed their clinical practice. Finally, in anticipation of its presentation at AHA 2019, Rasha gives an overview of the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA). Submit your question to Ankur via: podcast@radciffe-group.com.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Read MoreRead Less
In our final episode of the year, Ankur has an long conversation with Sukh Nijjer from Imperial College London about the most impactful, exciting and controversial clinical trials of 2019. Sukh and Ankur also discuss how these trials might change practice in the future, and how practice patterns and decisions differ between the US and the UK. In light of an emerging trend of shared decision making between physicians of different specialities and patients with a vast amount of information at their fingertips, Sukh and Ankur examine what tools they use to reconcile the growing data from clinical trials.
Trials discussed in detail include those presented at the ACC in New Orleans: PARTNER 3 & Evolut Low Risk on TAVR/TAVI, and SAFARI & COAPT on radial vs femoral access; presented at the ESC in Paris: THEMIS and ISAR-REACT 5 on DAPT post-PCI, DAPA-HF on SGLT2i’s for heart failure, and COMPLETE on PCI of non-culprit lesions in STEMI; presented at TCT in San Francisco: TWILIGHT on DAPT post-PCI, and EXCEL at 5 years on PCI vs CABG in left main CAD; and finally, presented at AHA in Philadelphia: ISCHEMIA on medical vs invasive approaches in ischemic events. Submit your question to Ankur via: podcast@radciffe-group.com.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Read More
Trials discussed in detail include those presented at the ACC in New Orleans: PARTNER 3 & Evolut Low Risk on TAVR/TAVI, and SAFARI & COAPT on radial vs femoral access; presented at the ESC in Paris: THEMIS and ISAR-REACT 5 on DAPT post-PCI, DAPA-HF on SGLT2i’s for heart failure, and COMPLETE on PCI of non-culprit lesions in STEMI; presented at TCT in San Francisco: TWILIGHT on DAPT post-PCI, and EXCEL at 5 years on PCI vs CABG in left main CAD; and finally, presented at AHA in Philadelphia: ISCHEMIA on medical vs invasive approaches in ischemic events. Submit your question to Ankur via: podcast@radciffe-group.com.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
All Episodes
Ankur is back with his second #AudioArticle! This week he spoke with Santiago Garcia from the Minneapolis Heart Institute about Santiago’s US Cardiology Review 13.1 article on the role of high-sensitivity cardiac troponin (hscTn) assays and their ability to rapidly rule in or rule out acute coronary syndrome (ACS) with improved sensitivity.
Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Read More
Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
In our first episode, Ankur explains his vision for and inspiration to start ‘Parallax’, and speaks with Chad Kliger from Lenox Hill Hospital in New York about conduction abnormalities after transcatheter aortic valve replacement (TAVR/TAVI), a review article published in US Cardiology Review 13.1 Ankur and Chad look at conduction abnormalities after TAVR/TAVI with a focus on basic conduction system anatomy in relation to the aortic valve, the mechanism, incidence, predisposing factors for occurrence, impact on mortality and finally, proposed treatment algorithms for management. Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Read More
In this inspiring episode, Dr Smith delves into the story behind his book and the motivating circumstances that led him to become an author. Dr Kalra asks Dr Smith about his experience as a leader during the pandemic as a surgeon. Dr Smith shares the story of his unconventional journey into medicine, emphasizing how hard physical labor built his resilience and prepared him for his residency. Dr Kalra also asks about Dr Smith's experience as a surgeon for President Bill Clinton in 2004.
Read More
In this insightful episode, we delve into Dr. Mandrola's career journey. He discusses how the beginnings of his career during a period of significant innovations and the reversal of expert opinions profoundly influenced his perspective on medicine, leading to a more conservative stance. Dr. Kalra then invites Dr. Mandrola to share the motivations that drive his work as a medical journalist and communicator, along with his methods of selecting studies to highlight in his writings and show.
Read More
In this candid and rich episode, Dr Fuster invites us to contemplate the concepts of mentorship and trust by recounting pivotal moments from his life, revealing how these principles propelled him towards a life of fulfilment.
Read More
Dr. Alasnag and Dr. Kalra provide a comprehensive review of the key highlights from ESC Congress 2023. Dr. Alasnag distills the background and latest evidence from key interventional trials, emphasizing their significance for patient care.
Tune in to discover the strategies that Dr. Kalra and Dr. Alasnag are currently employing and gain insights into how these data will shape their future decision-making in the catheterization laboratory. Don't miss this informative discussion at the forefront of interventional cardiology.
Read More
Tune in to discover the strategies that Dr. Kalra and Dr. Alasnag are currently employing and gain insights into how these data will shape their future decision-making in the catheterization laboratory. Don't miss this informative discussion at the forefront of interventional cardiology.
In this week's Parallax, Dr Ankur Kalra welcomes back Dr Jag Singh to discuss Dr Singh's recently published book, "Future Care," which delves into the exciting evolution of medicine over the next 5 to 10 years.
As we adapt to the changes brought about by the pandemic, Dr Singh outlines the necessary steps to foster a reality in which we can utilize these technologies to create more time for human connection.
Read More
As we adapt to the changes brought about by the pandemic, Dr Singh outlines the necessary steps to foster a reality in which we can utilize these technologies to create more time for human connection.